What matters is sales. The company has a massive mill stone6 Oct 2025 10:44
Around it's neck called NICE and NHS England. Even now only 9 of the 14 hospitals have installed the MT-RNR1. Why on Earth is that? NHS Scotland have apparently ordered a roll out of the MT-RNR1 throughout Scotland. Where are are with that? Lots of questions.
RE: Where are we at with the Scottish rollout? Where are we with the6 Oct 2025 09:38
14 hospital NHS England installations? Still only 9? Where are we with the International installations.......... especially the ones in the Middle East? My biggest concern is the quality of Genedrive's sales team. What International experience do they have? Have new sales staff been taken on that can speak 2 or 3 European languages fluently? Genedrive only need bare minimum staff for the UK sales as these sales are controlled by the NHS and NICE. Why does the company need £3m? £2m would be enough IMHO. If they are to be believed would see one FDA application in for the CYP2C19. Why on earth, I say again WHY ON EARTH do they NOT expect to apply for the MT-RNR! umtil the END of 2026! That is outrageous.
Where are we at with the Scottish rollout? Where are we with the5 Oct 2025 14:05
14 hospital NHS England installations? Still only 9? Where are we with the International installations.......... especially the ones in the Middle East? My biggest concern is the quality of Genedrive's sales team. What International experience do they have? None? Have new sales staff been taken on that can speak 2 or 3 European languages fluently? Genedrive only need bare minimum staff for the UK sales as these sales are controlled by the NHS and NICE. Why does the company need £3m? £2m would be enough IMHO. If they are to be believed would see one FDA application in for the CYP2C19. Why on earth, I say again WHY ON EARTH do they NOT expect to apply for the MT-RNR! umtil the END of 2026! That is outrageous.
Lung cancer biomarkers. Only Company in the World offering dual3 Oct 2025 17:58
Analysis with the prospect of finding twice the number of cancer biomarkers for potential Immunotherapy treatment. Angle's sales people should be all over this.
RE: Myriad Genetics potential contract. See link. If you think about it3 Oct 2025 16:18
Myriad have a lot to gain from having their customers blood sample CTC's (if there are any) analysed as well as the tissue sample. Once a deal is done they will have a bank of Parsortix machines in their lab(s) in the USA. So access to the best CTC samples currently available in the World as I understand, ideal for any type of analysis, including DNA. So for any currrently available tests ***AND and any FUTURE CTC tests that surface in the coming years*** they will have the best sample to look at. I would have thought there is very good reason to do a deal with Angle.
If Myriad don't do a deal with Angle Plc to get access to live, intact, uncontaminated circulating tumour cells I will be godsmacked, totally astonished and bewildered. Myriad want to look at CTC's, that is obvious by the RNS. Parsortix in the best machine for the job. How on Earth can these Companies NOT do a deal?
AIM shares. what share persent levels give you more say?3 Oct 2025 15:29
AI Overview
In limited companies like those on AIM, different share percentage levels give different levels of say: less than 25% is a passive stake, 25% or more offers blocking power on special resolutions, around 50% gives control, and 75% or more provides complete control over most company decisions.
Levels of Influence Based on Share Percentage
Minority Stake (Less than 25%):
You are a passive investor focused on profit, with little to no input in decision-making.
Influence (Around 25% or more):
This gives you blocking power on special resolutions (major decisions), but you don't have full control.
Control (Around 50%):
You become the key decision-maker and can shape the company's future strategy.
Maximum Control (Around 75% or more):
You have total authority to pass both ordinary and special resolutions.